Statistik Asas
| LEI | 549300XQQCQ7HCJKTW25 |
| CIK | 1609550 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Inspire Medical Systems, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 26, 2025 |
Inspire Medical Systems, Inc. Announces Departure of Chief Financial Officer Exhibit 99.1 Inspire Medical Systems, Inc. Announces Departure of Chief Financial Officer MINNEAPOLIS, MN - August 26, 2025 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its Chief Financial Officer, Rick |
|
| August 26, 2025 |
transitionandseparationa Exhibit 10.1 TRANSITION AND SEPARATION AGREEMENT THIS TRANSITION AND SEPARATION AGREEMENT (“Agreement,” or the “Transition Agreement”) is made and entered into by and between Richard J. Buchholz (“Executive”) and Inspire Medical Systems Inc. (the “Company”) and is made effective as of August 26, 2025 (the “Effective Date”). WHEREAS, Executive has been and is currently empl |
|
| August 26, 2025 |
SECURITIES AND EXCHANGE Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 22, 2025 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number) (I.R. |
|
| August 11, 2025 |
SECURITIES AND EXCHANGE Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2025 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number) (I.R. |
|
| August 11, 2025 |
a2025-8x11xxinspxxsharer Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program MINNEAPOLIS, MN – August 11, 2025 – Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that its B |
|
| August 4, 2025 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook MINNEAPOLIS, MN - August 4, 2025 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported |
|
| August 4, 2025 |
q22025investorpresentati Inspire Medical Systems, Inc. August 2025 NYSE: INSP © Inspire Medical Systems, Inc. All Rights Reserved. Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward |
|
| August 4, 2025 |
SECURITIES AND EXCHANGE Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2025 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S |
|
| August 4, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| June 13, 2025 |
SECURITIES AND EXCHANGE Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2025 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. |
|
| June 13, 2025 |
inspirewellsfargo2025pre © 2024 Inspire Medical Systems, Inc. All Rights Reserved Inspire Medical Systems, Inc. Wells Fargo 2025 MedTech Innovation Spotlight June 13, 2025 NYSE: INSP Disclaimer Current Sensor Inspire V Sensor Performance Therapy Evolution Built-in • Multiple electrodes capability • Enables new stim targets and sensing features Flexible Software Platform • Downloadable features for |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Inspire Medical Systems, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 5500 Wayzata Blvd, Suite 1600 Golden Valley, Minnesota 55416 (Addr |
|
| May 5, 2025 |
Inspire Medical Systems, Inc. May 2025 NYSE: INSP © Inspire Medical Systems, Inc. All Rights Reserved. Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms |
|
| May 5, 2025 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2025 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. E |
|
| May 5, 2025 |
SECURITIES AND EXCHANGE Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2025 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. E |
|
| May 5, 2025 |
EXHIBIT 10.4 INSPIRE MEDICAL SYSTEMS, INC. 2018 INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT AWARD GRANT NOTICE Inspire Medical Systems, Inc., a Delaware corporation, (the “Company”), pursuant to its 2018 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of performance stock units (“Performance Stock Units” or “PS |
|
| May 5, 2025 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, MN - May 5, 2025 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization |
|
| May 5, 2025 |
Inspire Medical Systems, Inc. Non -Employee Director Compensation Policy NON‐EMPLOYEE DIRECTOR COMPENSATION POLICY INSPIRE MEDICAL SYSTEMS, INC. (Last Amended: May 1, 2025) Non‐employee members of the board of directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non‐Employee Director Compensation Policy (this “Policy”). The cash and equity compensation described in this P |
|
| May 5, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 5, 2025 |
EXHIBIT 10.3 INSPIRE MEDICAL SYSTEMS, INC. 2018 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT Inspire Medical Systems, Inc., a Delaware corporation (the “Company”), pursuant to its 2018 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of Restricted Stock Units set |
|
| May 5, 2025 |
EXHIBIT 10.2 INSPIRE MEDICAL SYSTEMS, INC. 2018 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT Inspire Medical Systems, Inc., a Delaware corporation (the “Company”), pursuant to its 2018 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) an option to purchase the number of Shares set forth below (the |
|
| March 18, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check t |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confi |
|
| February 10, 2025 |
Subsidiaries of Inspire Medical Systems, Inc. Exhibit 21.1 SUBSIDIARIES OF THE COMPANY As of December 31, 2024, the Company had two subsidiaries: Inspire Medical Systems Europe GmbH, a German corporation Inspire Medical Systems Japan G.K., a Japanese corporation |
|
| February 10, 2025 |
SECURITIES AND EXCHANGE Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2025 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number) (I. |
|
| February 10, 2025 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results and Updates 2025 Outlook Inspire Reports Year-over-Year Revenue Growth of 25% and Earnings per Share Growth of 135% for the Fourth Quarter 2024 MINNEAPOLIS, Minnesota - February 10, 2025 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the developm |
|
| February 10, 2025 |
Inspire Medical Systems, Inc. Insider Trading Policy Inspire Medical Systems, Inc. Page 1 of 11 Title: Insider Trading Compliance Policy The official document is in electronic form with electronic signatures. Printed copies are considered uncontrolled. Effective Date: Feb 3, 2025 Exhibit 19.1 This Insider Trading Compliance Policy (this “Policy”) of Inspire Medical Systems, Inc. (the “Company”) is intended to prevent insider trading or allegations o |
|
| February 10, 2025 |
Employment Agreement between the Company and Jason Kelly Exhibit 10.19 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of December 20, 2024 (the “Effective Date”), by and between Inspire Medical Systems, Inc. (“Inspire” or the “Company”), a Delaware corporation, and Jason Kelly (“Executive”). WHEREAS, Executive desires to provide services to the Company on the terms herein provided. NOW, THERE |
|
| February 10, 2025 |
Inspire Medical Systems, Inc. February 2025 NYSE: INSP © Inspire Medical Systems, Inc. All Rights Reserved. Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by |
|
| February 10, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| January 13, 2025 |
© 2024 Inspire Medical Systems, Inc. All Rights Reserved Inspire Medical Systems, Inc. JP Morgan Healthcare Conference INSPIRE CONFIDENTIAL. Inspire is a public company and has an Insider Trading Policy. The content in this deck is not to be shared with anybody outside of Inspire Medical Systems, Inc. It is for internal review and discussion only January 13, 2025 NYSE: INSP JP Morgan Investor Upda |
|
| January 13, 2025 |
SECURITIES AND EXCHANGE Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number) (I.R |
|
| January 13, 2025 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2024 and Provides Initial 2025 Revenue Guidance Inspire Reports Year-over-Year Revenue Growth of 25% for the Fourth Quarter and 28% for the Full Year 2024 MINNEAPOLIS, MN - January 13, 2025 - Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology com |
|
| November 12, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 4, 2024 |
SECURITIES AND EXCHANGE Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number) (I.R |
|
| November 4, 2024 |
Inspire Medical Systems, Inc. November 2024 NYSE: INSP © Inspire Medical Systems, Inc. All Rights Reserved. Disclaimer 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements b |
|
| November 4, 2024 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Third Quarter 2024 Financial Results and Updates 2024 Outlook Inspire Reports Year-over-Year Revenue Growth of 33% and Earnings per Share of $0.60 in the Third Quarter MINNEAPOLIS, MN - November 4, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercializ |
|
| November 4, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| August 6, 2024 |
Exhibit 99.3 Inspire Medical Systems, Inc. Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program MINNEAPOLIS, MN — August 6, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today ann |
|
| August 6, 2024 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Second Quarter 2024 Financial Results and Updates 2024 Outlook Inspire Reports Year-over-Year Revenue Growth of 30% in the Second Quarter MINNEAPOLIS, MN - August 6, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally i |
|
| August 6, 2024 |
Inspire Medical Systems, Inc. August 2024 NYSE: INSP © Inspire Medical Systems, Inc. All Rights Reserved. Disclaimer 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by |
|
| August 6, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 6, 2024 |
mployment Agreement between the Company and Melissa Mann 1 Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of June 5, 2024 (the “Effective Date”), by and between Inspire Medical Systems, Inc. (“Inspire” or the “Company”), a Delaware corporation, and Melissa Mann (“Executive”). WHEREAS, Executive desires to provide services to the Company on the terms herein provided. NOW, THEREFOR |
|
| August 6, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 2, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 2, 2024 |
Inspire Medical Systems, Inc. Announces FDA Approval of the Inspire V System Exhibit 99.1 Inspire Medical Systems, Inc. Announces FDA Approval of the Inspire V System MINNEAPOLIS, MN – August 2, 2024 – Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the FDA approval of the Inspire V |
|
| July 29, 2024 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Preliminary Results for Second Quarter of 2024 and Updates 2024 Revenue Outlook MINNEAPOLIS, MN - July 29, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced cert |
|
| July 29, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 22, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 7, 2024 |
Inspire Medical Systems, Inc. May 2024 NYSE: INSP © Inspire Medical Systems, Inc. All Rights Reserved. Disclaimer 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by ter |
|
| May 7, 2024 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces First Quarter 2024 Financial Results and Updates 2024 Outlook Inspire Reports Year-over-Year Revenue Growth of 28% in the First Quarter and Expects Profitability for the Full Year 2024 MINNEAPOLIS, Minnesota - May 7, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercia |
|
| May 7, 2024 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 7, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 7, 2024 |
Inspire Medical Systems, Inc. Non-Employee Director Compensation Policy non-employeedirectorcomp NON‐EMPLOYEE DIRECTOR COMPENSATION POLICY INSPIRE MEDICAL SYSTEMS, INC. |
|
| May 7, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf |
|
| March 19, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy |
|
| February 13, 2024 |
INSP / Inspire Medical Systems, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01194-inspiremedicalsystem.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Inspire Medical Systems Inc Title of Class of Securities: Common Stock CUSIP Number: 457730109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate bo |
|
| February 9, 2024 |
Inspire Medical Systems, Inc. Recovery of Erroneously Awarded Compensation Policy RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION POLICY Inspire Medical Systems, Inc. (as of: November 27, 2023) Inspire Medical Systems, Inc. (the “Company”) has adopted this Recovery of Erroneously Awarded Compensation Policy (the “Policy”) to provide for the Company’s criteria and process for recovering certain Incentive-based Compensation erroneously awarded to or earned or received by current and |
|
| February 9, 2024 |
Subsidiaries of Inspire Medical Systems, Inc. Exhibit 21.1 SUBSIDIARIES OF THE COMPANY As of December 31, 2023, the Company had two subsidiaries: Inspire Medical Systems Europe GmbH, a German corporation Inspire Medical Systems Japan G.K., a Japanese corporation |
|
| February 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 6, 2024 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results and Reaffirms 2024 Outlook Inspire Reports First Quarter with Operating Income and Year-over-Year Revenue Growth of 40% in the Fourth Quarter MINNEAPOLIS, Minnesota - February 6, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development |
|
| February 6, 2024 |
1 Inspire Medical Systems, Inc. February 2024 NYSE: INSP © Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward- |
|
| February 6, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 5, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 5, 2024 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Chair Marilyn Carlson Nelson to Retire and Timothy P. Herbert named Chair and Chief Executive Officer Gary L. Ellis to serve as Lead Independent Director MINNEAPOLIS, MN – February 5, 2024 – Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally |
|
| January 26, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 26, 2024 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Jerry C. Griffin, M.D. to Retire from its Board after Sixteen Years of Service MINNEAPOLIS, MN – January 26, 2024 – Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today |
|
| January 8, 2024 |
1 Inspire Medical Systems, Inc. JP Morgan Healthcare Conference January 8, 2024 NYSE: INSP © Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In so |
|
| January 8, 2024 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance MINNEAPOLIS, Minnesota - January 8, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive s |
|
| January 8, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 28, 2023 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Myriam J. Curet, M.D. to its Board of Directors Company adds further expertise in medical device industry R&D, regulatory affairs and commercialization MINNEAPOLIS, MN – December 28, 2023 – Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the developmen |
|
| December 28, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File |
|
| November 7, 2023 |
Inspire Medical Systems, Inc. November 2023 NYSE: INSP 1 © Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, you can identify forward |
|
| November 7, 2023 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Third Quarter 2023 Financial Results and Updates 2023 Outlook Inspire Reports Year-over-Year Revenue Growth of 40% in the Third Quarter MINNEAPOLIS, Minnesota - November 7, 2023 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive s |
|
| November 7, 2023 |
Employment Agreement between the Company and Charisse Sparks dated July 27, 2023 US.358543369.01 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of July 27, 2023 (the “Effective Date”), by and between Inspire Medical Systems, Inc. (“Inspire” or the “Company”), a Delaware corporation, and Charisse Y. Sparks, M.D. (“Executive”). WHEREAS, Executive currently serves as a member of the Company’s Board of Dire |
|
| November 7, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 7, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| August 1, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 27, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 1, 2023 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Second Quarter 2023 Financial Results and Updates 2023 Outlook Inspire Reports Year-over-Year Revenue Growth of 65% in the Second Quarter MINNEAPOLIS, Minnesota - August 1, 2023 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive s |
|
| August 1, 2023 |
q22023presentationfinal Inspire Medical Systems, Inc. August 2023 NYSE: INSP 1 © Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, yo |
|
| August 1, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 1, 2023 |
Inspire Medical Systems, Inc. Non-Employee Director Compensation Policy ex10-1nonxempdircomppoli NON-EMPLOYEE DIRECTOR COMPENSATION POLICY INSPIRE MEDICAL SYSTEMS, INC. |
|
| August 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 1, 2023 |
Employment Agreement between the Company and Carlton Weatherby ex10-2empagreementweathe 1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of June 13, 2023 (the “Effective Date”), by and between Inspire Medical Systems, Inc. |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commiss |
|
| May 22, 2023 |
wellfargospotlight22may © Inspire Medical Systems, Inc. All Rights Reserved Wells Fargo Spotlight Series May 2023 © Inspire Medical Systems, Inc. All Rights Reserved Inspire SleepSync™ Patient Journey © Inspire Medical Systems, Inc. All Rights Reserved Supporting Patients on their Path to Inspire 3 Implant Fine- tune ActivationInspire Advisor Care Program (ACP) DISE/ Prior Authorization Patient ed |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commissi |
|
| May 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 2, 2023 |
q12023presentationfinal Inspire Medical Systems, Inc. May 2023 NYSE: INSP 1 © Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, you c |
|
| May 2, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 2, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 2, 2023 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces First Quarter 2023 Financial Results and Updates 2023 Outlook Inspire Reports Year-over-Year Revenue Growth of 84% in the First Quarter MINNEAPOLIS, Minnesota - May 2, 2023 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive soluti |
|
| March 17, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf |
|
| February 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 10, 2023 |
Subsidiaries of Inspire Medical Systems, Inc. Exhibit 21.1 SUBSIDIARIES OF THE COMPANY As of December 31, 2022, the Company had one subsidiary: Inspire Medical Systems Europe GmbH, a German corporation |
|
| February 10, 2023 |
ex10-10formofoptionagree INSPIRE MEDICAL SYSTEMS, INC. 2018 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT (As Amended and Restated on January 31, 2023) Inspire Medical Systems, Inc., a Delaware corporation (the “Company”), pursuant to its 2018 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) an opt |
|
| February 9, 2023 |
INSP / Inspire Medical Systems Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01154-inspiremedicalsystem.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Inspire Medical Systems Inc. Title of Class of Securities: Common Stock CUSIP Number: 457730109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate b |
|
| February 7, 2023 |
Inspire Medical Systems, Inc. February 2023 NYSE: INSP 1 © Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, you can identify forward |
|
| February 7, 2023 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance Inspire Reports First Profitable Quarter and Year-over-Year Revenue Growth of 76% in the Fourth Quarter MINNEAPOLIS, Minnesota - February 7, 2023 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commer |
|
| February 7, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 7, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Com |
|
| February 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 7, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Comm |
|
| January 9, 2023 |
EX-99.1 2 jpmconferencepresentatio.htm EX-99.1 1 Inspire Medical Systems, Inc. JP Morgan Healthcare Conference January 9, 2023 NYSE: INSP © Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historic |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Comm |
|
| January 9, 2023 |
EX-99.1 2 insp2022-q4prereleaseex991.htm EX-99.1 Exhibit 99.1 Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022 MINNEAPOLIS, Minnesota - January 9, 2023 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with |
|
| November 10, 2022 |
INSP / Inspire Medical Systems Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Inspire Medical Systems Inc. Title of Class of Securities: Common Stock CUSIP Number: 457730109 Date of Event Which Requires Filing of this Statement: October 31, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| November 1, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Com |
|
| November 1, 2022 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Third Quarter 2022 Financial Results and Updates 2022 Outlook Inspire Reports Year-over-Year Revenue Growth of 77% in the Third Quarter MINNEAPOLIS, Minnesota - November 1, 2022 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive s |
|
| August 24, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 18, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation or org |
|
| August 15, 2022 |
1,000,000 Shares Inspire Medical Systems, Inc. Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration Statement No. 333-237654? PROSPECTUS SUPPLEMENT (to Prospectus dated April 13, 2020) 1,000,000 Shares Inspire Medical Systems, Inc. Common Stock ? We are offering 1,000,000 shares of our common stock, par value $0.001 per share. Our common stock is listed on the New York Stock Exchange under the symbol ?INSP.? On August 10, 2022, t |
|
| August 15, 2022 |
Exhibit 1.1 EXECUTION VERSION INSPIRE MEDICAL SYSTEMS, INC. (a Delaware corporation) 1,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: August 11, 2022 INSPIRE MEDICAL SYSTEMS, INC. (a Delaware corporation) 1,000,000 Shares of Common Stock UNDERWRITING AGREEMENT August 11, 2022 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 Ladies and Gentlemen: Inspire Medical System |
|
| August 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Comm |
|
| August 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Inspire Medical Systems, Inc. |
|
| August 11, 2022 |
Subject to Completion Preliminary Prospectus Supplement dated August 11, 2022 TABLE OF CONTENTS The information in this prospectus supplement is not complete and may be changed. |
|
| August 2, 2022 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Second Quarter 2022 Financial Results and Updates 2022 Outlook Inspire Reports Year-over-Year Revenue Growth of 73% in the Second Quarter MINNEAPOLIS, Minnesota - August 2, 2022 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive s |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commis |
|
| August 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commi |
|
| August 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commis |
|
| June 22, 2022 |
1 Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of June 15, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Agent?), |
|
| May 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commissi |
|
| May 4, 2022 |
1 Inspire Medical Systems, Inc. May 2022 NYSE: INSP ? Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, you can identify forward-look |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commissi |
|
| May 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commi |
|
| May 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. |
|
| May 3, 2022 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces First Quarter 2022 Financial Results and Updates 2022 Outlook Inspire Reports Year-over-Year Revenue Growth of 72% in the First Quarter MINNEAPOLIS, Minnesota - May 3, 2022 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive soluti |
|
| March 16, 2022 |
Definitive Proxy Statement on Schedule 14A filed with the SEC on March 16, 2022 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? ? ? Check the appropriate box: ? ? ?? ? ? |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? ? ? Check the appropriate box: ? ? ?? ? ? Preliminary Proxy |
|
| February 15, 2022 |
Subsidiaries of Inspire Medical Systems, Inc. Exhibit 21.1 SUBSIDIARIES OF THE COMPANY The Company has no subsidiaries. |
|
| February 15, 2022 |
Exhibit 10.14 INSPIRE MEDICAL SYSTEMS, INC. 2018 INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT AWARD GRANT NOTICE Inspire Medical Systems, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2018 Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?), an award of performance stock units (?Performance Stock Units? or ?P |
|
| February 15, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Co |
|
| February 10, 2022 |
1 Inspire Medical Systems, Inc. February 2022 NYSE: INSP ? Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, you can identify forward |
|
| February 10, 2022 |
INSP / Inspire Medical Systems Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Inspire Medical Systems Inc. Title of Class of Securities: Common Stock CUSIP Number: 457730109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 8, 2022 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Guidance Accelerated Patient Demand and Increased Center Capacity Drives Year-over-Year Revenue Growth of 70% and 102% in the Fourth Quarter and Full Year, Respectively MINNEAPOLIS, Minnesota - February 8, 2022 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medica |
|
| February 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 8, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 4, 2022 |
1 Inspire Medical Systems, Inc. January 2022 NYSE: INSP ? Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, you can identify forward- |
|
| January 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 4, 2022 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2021 MINNEAPOLIS, Minnesota - January 4, 2022 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced ce |
|
| January 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2022 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Comm |
|
| November 3, 2021 |
1 Inspire Medical Systems, Inc. November 2021 NYSE: INSP ? Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, you can identify forward |
|
| November 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Com |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 2, 2021 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Third Quarter 2021 Financial Results and Updates 2021 Outlook MINNEAPOLIS, Minnesota - November 2, 2021 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today reported fi |
|
| November 2, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. |
|
| August 4, 2021 |
1 Inspire Medical Systems, Inc. August 2021 NYSE: INSP ? Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, you can identify forward-l |
|
| August 4, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commi |
|
| August 3, 2021 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Second Quarter 2021 Financial Results and Updates 2021 Outlook MINNEAPOLIS, Minnesota - August 3, 2021 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today reported fin |
|
| August 3, 2021 |
Inspire Medical Systems, Inc. Non-Employee Director Compensation Policy Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY INSPIRE MEDICAL SYSTEMS, INC. (Last Amended: April 29, 2021) Non-employee members of the board of directors (the ?Board?) of Inspire Medical Systems, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this ?Policy?). The cash and equity compensation des |
|
| August 3, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. |
|
| August 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commiss |
|
| June 7, 2021 |
1 Inspire Medical Systems, Inc. June 2021 NYSE: INSP ? Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, you can identify forward-loo |
|
| May 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commiss |
|
| May 21, 2021 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Positive Coverage Policy Issued by Anthem for Inspire Therapy MINNEAPOLIS, Minnesota - May 20, 2021 ? Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (?OSA?), announced tod |
|
| May 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commissi |
|
| May 5, 2021 |
1 In sp ir e M e d ic a l S y st e m s, I n c . M a y 2 0 2 1 N Y S E : IN S P ? I n s p ir e M e d ic a l S y s te m s , In c . A ll R ig h ts R e s e rv e d IN S P IR E C O N F ID E N T IA L D is c la im e r T h is p re s e n ta ti o n c o n ta in s f o rw a rd -l o o k in g s ta te m e n ts w ith in t h e m e a n in g o f th e P ri v a te S e c u ri tie s L iti g a tio n R e fo rm A c t o f 1 9 |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commissi |
|
| May 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. |
|
| May 4, 2021 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces First Quarter 2021 Financial Results and Updates 2021 Outlook MINNEAPOLIS, Minnesota - May 4, 2021 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today reported financi |
|
| May 4, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commi |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ?o Check the appropriate box: ?? Preliminary Proxy Statement ?? Conf |
|
| March 16, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Prelimina |
|
| February 24, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 24, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Co |
|
| February 24, 2021 |
INSPIRE MEDICAL SYSTEMS, INC. 2018 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT Inspire Medical Systems, Inc., a Delaware corporation (the ?Company?), pursuant to its 2018 Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?) the number of Restricted Stock Units set forth below |
|
| February 24, 2021 |
Subsidiaries of Inspire Medical Systems, Inc. Exhibit 21.1 SUBSIDIARIES OF THE COMPANY The Company has no subsidiaries. |
|
| February 24, 2021 |
Employment Agreement between the Company and Bryan Phillips EXHIBIT 10.20 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made and entered into as of October 14, 2020 (the ?Effective Date?), by and between Inspire Medical Systems, Inc. (?Inspire? or the ?Company?), a Delaware corporation, and Bryan Phillips (?Executive?). WHEREAS, Executive desires to provide services to the Company on the terms herein provided. NOW, THE |
|
| February 24, 2021 |
inspcopres2021-02secxfl 1 Inspire Medical Systems, Inc. February 2021 NYSE: INSP © Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, |
|
| February 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Co |
|
| February 23, 2021 |
EX-99.1 2 insp2020-q4pressreleaseex9.htm EX-99.1 Exhibit 99.1 Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Guidance MINNEAPOLIS, Minnesota - February 23, 2021 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive sol |
|
| February 12, 2021 |
CUSIP No. 457730109 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the ?Schedule 13G?), with respect to the Common Stock of Inspire Medical Systems, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act o |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Inspire Medical Systems Inc. Title of Class of Securities: Common Stock CUSIP Number: 457730109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1 |
|
| January 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2021 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Comm |
|
| January 7, 2021 |
EX-99.1 2 inspcopres2021-01sec.htm EX-99.1 1 Inspire Medical Systems, Inc. January 2021 NYSE: INSP © Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statement |
|
| November 9, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Com |
|
| November 9, 2020 |
inspirecompanypresentati Inspire Medical Systems, Inc. November 2020 NYSE: INSP 1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘w |
|
| November 2, 2020 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Third Quarter 2020 Financial Results and Updates 2020 Outlook MINNEAPOLIS, Minnesota - November 2, 2020 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today reported fi |
|
| November 2, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Com |
|
| November 2, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. |
|
| October 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Com |
|
| August 5, 2020 |
inspirecompanypresentati Inspire Medical Systems, Inc. August 2020 NYSE: INSP 1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘wil |
|
| August 5, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commi |
|
| August 4, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. |
|
| August 4, 2020 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Second Quarter 2020 Financial Results and Updates 2020 Outlook MINNEAPOLIS, Minnesota - August 4, 2020 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today reported fin |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commi |
|
| July 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commiss |
|
| June 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commiss |
|
| June 8, 2020 |
Employment Agreement between the Company and Philip Ebeling EX-10.1 2 inspemploymentagreemente.htm EX-10.1 EXHIBIT 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of June 1, 2020 (the “Effective Date”), by and between Inspire Medical Systems, Inc. (“Inspire” or the “Company”), a Delaware corporation, and Philip Ebeling (“Executive”). WHEREAS, Executive desires to provide services to the Comp |
|
| June 8, 2020 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Appointment of Medical Technology Industry Veteran Phil Ebeling as Chief Operating Officer MINNEAPOLIS, MN – June 8, 2020 – Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea |
|
| May 6, 2020 |
EX-99.1 2 inspcopres05mayx2020-fl.htm EX-99.1 Inspire Medical Systems, Inc. May 2020 NYSE: INSP 1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such |
|
| May 6, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commissi |
|
| May 5, 2020 |
Inspire Medical Systems, Inc. Announces First Quarter 2020 Financial Results Exhibit 99.1 Inspire Medical Systems, Inc. Announces First Quarter 2020 Financial Results MINNEAPOLIS, Minnesota - May 5, 2020 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarte |
|
| May 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. |
|
| May 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commissi |
|
| May 4, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commi |
|
| April 16, 2020 |
Exhibit 1.1 EXECUTION VERSION INSPIRE MEDICAL SYSTEMS, INC. (a Delaware corporation) 2,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: April 13, 2020 INSPIRE MEDICAL SYSTEMS, INC. (a Delaware corporation) 2,000,000 Shares of Common Stock UNDERWRITING AGREEMENT April 13, 2020 BofA Securities, Inc. J.P. Morgan Securities LLC Goldman Sachs & Co. LLC as Representatives of the several Unde |
|
| April 16, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 13, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commi |
|
| April 15, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| April 13, 2020 |
Inspire Medical Systems, Inc. Provides First Quarter and Full Year 2020 Update EX-99.1 2 tm2012413d4ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Inspire Medical Systems, Inc. Provides First Quarter and Full Year 2020 Update MINNEAPOLIS, Minnesota – April 13, 2020 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apne |
|
| April 13, 2020 |
INSP / Inspire Medical Systems, Inc. S-3ASR - - S-3ASR Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on April 13, 2020 Registration No. |
|
| April 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 13, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commi |
|
| April 13, 2020 |
Subject to Completion Preliminary Prospectus Supplement dated April 13, 2020 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(5) Registration Statement No. |
|
| April 13, 2020 |
Exhibit 4.3 INSPIRE MEDICAL SYSTEMS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Es |
|
| March 17, 2020 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Prox |
|
| March 16, 2020 |
INSP / Inspire Medical Systems, Inc. DEFA14A - - DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf |
|
| March 16, 2020 |
INSP / Inspire Medical Systems, Inc. DEF 14A - - DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy |
|
| February 26, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Co |
|
| February 26, 2020 |
inspirecompanypresentati Inspire Medical Systems, Inc. February 2020 NYSE: INSP 1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘w |
|
| February 25, 2020 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results and Provides 2020 Guidance MINNEAPOLIS, Minnesota - February 25, 2020 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, |
|
| February 25, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 25, 2020 |
Exhibit 4.6 DESCRIPTION OF CAPITAL STOCK Capital Structure The following description of the capital stock of Inspire Medical Systems, Inc. (the “Company,” “we,” “us,” and “our”) and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified in their entirety by reference to the full text of our amended and restated ce |
|
| February 25, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2020 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Co |
|
| February 25, 2020 |
Subsidiaries of Inspire Medical Systems, Inc. Exhibit 21.1 SUBSIDIARIES OF THE COMPANY The Company has no subsidiaries. |
|
| February 14, 2020 |
INSP / Inspire Medical Systems, Inc. / ORBIMED ADVISORS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Inspire Medical Systems, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45773010 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing o |
|
| February 5, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Inspire Medical Systems, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 457730109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing |
|
| February 5, 2020 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Inspire Medical Systems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 457730109 (CUS |
|
| February 5, 2020 |
EX-99.A EXHIBIT A JOINT FILING STATEMENT We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Inspire Medical Systems, Inc. is filed on behalf of each of us. Dated: February 5, 2020 SYNERGY LIFE SCIENCE PARTNERS, LP By: Synergy Venture Partners, LLC Its: General Partner By: /s/ William N. Starling, Jr. Name: Wi |
|
| November 12, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2019 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Co |
|
| November 12, 2019 |
inspcopres2019nov Inspire Medical Systems, Inc. November 2019 NYSE: INSP 1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by te |
|
| November 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2019 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Com |
|
| November 5, 2019 |
EX-99.1 2 insp2019-q3pressreleas.htm EX-99.1 Exhibit 99.1 Inspire Medical Systems, Inc. Announces Third Quarter 2019 Financial Results and Increases 2019 Outlook MINNEAPOLIS, Minnesota - November 5, 2019 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients |
|
| November 5, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. |
|
| September 4, 2019 |
inspirecompanypresentati Inspire Medical Systems, Inc. September 2019 NYSE: INSP 1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statemen |
|
| September 4, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 4, 2019 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation or o |
|
| August 6, 2019 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces Second Quarter 2019 Financial Results and Increases 2019 Outlook MINNEAPOLIS, Minnesota - August 6, 2019 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, reported financi |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2019 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commi |
|
| August 6, 2019 |
Inspire Medical Systems, Inc. Non-Employee Director Compensation Policy Exhibit 10.1 Non-Employee Director Compensation Policy Non-employee members of the board of directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation described in this Policy shall be paid or be made, as applicable |
|
| August 6, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. |
|
| July 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2019 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2019 |
inspirecompanypresentati Inspire Medical Systems, Inc. s May 2019 NYSE: INSP Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by |
|
| May 9, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2019 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation or organiz |
|
| May 8, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2019 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation) (Commissi |
|
| May 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2019 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation or organiz |
|
| May 7, 2019 |
Exhibit 99.1 Inspire Medical Systems, Inc. Announces First Quarter 2019 Financial Results and Increases 2019 Outlook MINNEAPOLIS, Minnesota - May 7, 2019 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, reported financial r |
|
| May 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. |
|
| March 29, 2019 |
a20190327oxfordinspsecon EXHIBIT 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of March 27, 2019, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Col |
|
| March 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2019 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation or orga |
|
| March 20, 2019 |
INSP / Inspire Medical Systems, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 20, 2019 |
INSP / Inspire Medical Systems, Inc. DEF 14A TABLE OF CONTENTS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| February 27, 2019 |
inspirecompanypresentati Inspire Medical Systems, Inc. s February 2019 NYSE: INSP Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statement |
|
| February 27, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2019 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation or o |
|
| February 26, 2019 |
Subsidiaries of Inspire Medical Systems, Inc. EX-21.1 2 a2018-10kex21x1.htm EXHIBIT 21.1 Exhibit 21.1 SUBSIDIARIES OF THE COMPANY The Company has no subsidiaries. |
|
| February 26, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2019 INSPIRE MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38468 26-1377674 (State or other jurisdiction of incorporation or o |
